Trial Outcomes & Findings for Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease (NCT NCT03978130)

NCT ID: NCT03978130

Last Updated: 2025-06-06

Results Overview

Change in 6MWD, reflective of functional capacity, is measured by the 6-minute walk test (6MWT). The 6-minute walk test (6MWT) is a submaximal exercise test in which the pace is self-selected by the participant. The 6MWT will be performed during baseline hospitalization and at the 3-month follow-up visit by a blinded research nurse. The outcome change in 6MWD is calculated as 3 month 6MWD minus baseline 6MWD.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

400 participants

Primary outcome timeframe

Baseline, 3 months

Results posted on

2025-06-06

Participant Flow

Participant milestones

Participant milestones
Measure
mHealth-CR
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
Participants in this arm receive usual care.
Overall Study
STARTED
298
102
Overall Study
COMPLETED
271
85
Overall Study
NOT COMPLETED
27
17

Reasons for withdrawal

Reasons for withdrawal
Measure
mHealth-CR
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
Participants in this arm receive usual care.
Overall Study
Lost to Follow-up
13
14
Overall Study
Withdrawal by Subject
12
2
Overall Study
Adverse Event
2
1

Baseline Characteristics

Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=102 Participants
Participants in this arm receive usual care.
Total
n=400 Participants
Total of all reporting groups
Age, Continuous
71 years
n=99 Participants
71 years
n=107 Participants
71 years
n=206 Participants
Sex: Female, Male
Female
82 Participants
n=99 Participants
27 Participants
n=107 Participants
109 Participants
n=206 Participants
Sex: Female, Male
Male
216 Participants
n=99 Participants
75 Participants
n=107 Participants
291 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
23 Participants
n=99 Participants
11 Participants
n=107 Participants
34 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
275 Participants
n=99 Participants
91 Participants
n=107 Participants
366 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
11 Participants
n=99 Participants
6 Participants
n=107 Participants
17 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
27 Participants
n=99 Participants
9 Participants
n=107 Participants
36 Participants
n=206 Participants
Race (NIH/OMB)
White
229 Participants
n=99 Participants
74 Participants
n=107 Participants
303 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
31 Participants
n=99 Participants
13 Participants
n=107 Participants
44 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
298 participants
n=99 Participants
102 participants
n=107 Participants
400 participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline, 3 months

Change in 6MWD, reflective of functional capacity, is measured by the 6-minute walk test (6MWT). The 6-minute walk test (6MWT) is a submaximal exercise test in which the pace is self-selected by the participant. The 6MWT will be performed during baseline hospitalization and at the 3-month follow-up visit by a blinded research nurse. The outcome change in 6MWD is calculated as 3 month 6MWD minus baseline 6MWD.

Outcome measures

Outcome measures
Measure
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=102 Participants
Participants in this arm receive usual care.
Persistently High
Participants who had continuously high engagement with the program.
Change in 6-minute Walking Distance (6MWD)
41.2 meters
Standard Deviation 1.5
25.6 meters
Standard Deviation 2.7

PRIMARY outcome

Timeframe: 3 months

Weekly engagement will be measured as the fraction of the following 11 elements completed each week: (1-7) daily entry of exercise data and relative perceived exertion (RPE); (8) completed weekly phone call with exercise therapist; (9) at least one electronic communication with exercise therapist; (10) watching educational video (which will vary by week); and (11) at least one home BP measurement. Engagement will be assessed as a pseudo-continuous outcome, as the score can range from 0% (0 activities completed) to 100% (all 11 activities completed). The participants in the intervention arm will be grouped into 3 engagement phenotypes based on their scores: 1) Persistently Low, 2) Intermediate Declining, and 3) Persistently High.

Outcome measures

Outcome measures
Measure
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=298 Participants
Participants in this arm receive usual care.
Persistently High
n=298 Participants
Participants who had continuously high engagement with the program.
Number of Participants in Each Engagement Phenotype on Intervention Arm
81 Participants
93 Participants
124 Participants

SECONDARY outcome

Timeframe: 3 months

Using the SMART goal framework, GAS describes the person's expected level of goal achievement over 3 months, ranging from no change (scored as -2) to much better than expected (scored as +2) out of a 5 point-scale. Scales are dynamically set according to a person's needs, while measurement of attainment is standardized. Overall score is calculated by incorporating the goal of outcomes scores into an aggregated t-score. Goal attainment, through goal setting, is an especially important outcome in older adults who may begin an intervention with a variety of deficits (therefore necessitating individualized therapy towards realistic goals).

Outcome measures

Outcome measures
Measure
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=102 Participants
Participants in this arm receive usual care.
Persistently High
Participants who had continuously high engagement with the program.
Percentage of Participants With Goal Attainment, as Measured Using a 5-point Goal Attainment Scale (GAS)
25.7 Percentage of participants
20.9 Percentage of participants

SECONDARY outcome

Timeframe: Month 3

The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. For the SF-12, the 3 month score will be analyzed using a threshold of 5 points in SF-12 physical component score (PCS) as a clinically meaningful change.

Outcome measures

Outcome measures
Measure
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=102 Participants
Participants in this arm receive usual care.
Persistently High
Participants who had continuously high engagement with the program.
12-Item Short Form Survey (SF-12) Score
46.3 score on a scale
Standard Deviation 1
48.2 score on a scale
Standard Deviation 1.1

SECONDARY outcome

Timeframe: Baseline, 3 months

The Seattle Angina Questionnaire-7 (SAQ-7) is a self-administered questionnaire that measures patient-reported health measures related to coronary artery disease (CAD). The SAQ-7 is scored from 0 to 100, with higher scores indicating better health status, less frequent angina, and better quality of life (0-24: Poor health status; 25-49: Fair; 50-74: Good; 75-100: Excellent). For SAQ-7, we will analyze at a single time point (3 months) the number of participants who have residual angina (SAQ-7\<100) vs. no angina (SAQ-7=100).

Outcome measures

Outcome measures
Measure
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=102 Participants
Participants in this arm receive usual care.
Persistently High
Participants who had continuously high engagement with the program.
Percentage of Participants With no Residual Angina, as Measured by the Seattle Angina Questionnaire 7 (SAQ-7) (Disease-specific Health Status)
25.7 Percentage of participants
20.9 Percentage of participants

SECONDARY outcome

Timeframe: Baseline, 3 months

Defined as any improvement or worsening in basic (BADLs) or instrumental (IADLs) over 3 months. The Bristol Activities of Daily Living Scale (BADL) measures basic self-care behaviors: feeding, toileting, bathing, dressing, and ambulating. The score is interpreted based on the total score, which ranges from 0 to 60. Higher scores indicate greater independence in daily living activities. The Lawton Instrumental Activities of Daily Living (IADL) scale measures activities that allow a person to live independently (e.g. food preparation, medication management, transportation, shopping, managing finances, using the telephone, and housekeeping). The total score ranges from 0 (low function, dependent) to 8 (high function, independent) for women, and 0 through 5 for men.

Outcome measures

Outcome measures
Measure
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=102 Participants
Participants in this arm receive usual care.
Persistently High
Participants who had continuously high engagement with the program.
Percentage of Participants Who Have Any ADL or IADL Impairment
9.7 percentage of participants
10.6 percentage of participants

SECONDARY outcome

Timeframe: 1 Year

Defined as number of participants who were readmitted into the hospital with an overnight stay (including observation) in any hospital within 12 months of hospitalization. Data are obtainable via the electronic health record (EHR).

Outcome measures

Outcome measures
Measure
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=102 Participants
Participants in this arm receive usual care.
Persistently High
Participants who had continuously high engagement with the program.
Number of Hospital Readmissions
56 Participants
16 Participants

SECONDARY outcome

Timeframe: 1 Year

Data are obtainable via the electronic health record (EHR).

Outcome measures

Outcome measures
Measure
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=102 Participants
Participants in this arm receive usual care.
Persistently High
Participants who had continuously high engagement with the program.
Number of Participants Who Died From Any Cause
5 Participants
1 Participants

Adverse Events

mHealth-CR

Serious events: 19 serious events
Other events: 64 other events
Deaths: 5 deaths

Usual Care

Serious events: 4 serious events
Other events: 18 other events
Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure
mHealth-CR
n=298 participants at risk
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=102 participants at risk
Participants in this arm receive usual care.
Musculoskeletal and connective tissue disorders
Fall
0.67%
2/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Investigations
Abnormal labs
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Renal and urinary disorders
Urinary obstruction
0.00%
0/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.98%
1/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Surgical and medical procedures
Planned procedure
0.00%
0/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.98%
1/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Immune system disorders
Cancer
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Musculoskeletal and connective tissue disorders
Dizziness
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Respiratory, thoracic and mediastinal disorders
COVID
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Gastrointestinal disorders
GI Issues
1.0%
3/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Gastrointestinal disorders
Difficulty Swallowing
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Cardiac disorders
Chest pain, tightness, angina
0.67%
2/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Cardiac disorders
Planned procedure
0.67%
2/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.98%
1/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Cardiac disorders
Heart Failure
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Cardiac disorders
Myocardial Infarction
0.00%
0/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.98%
1/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Cardiac disorders
Arrythmia, claudication, hypertensive or hypotensive urgency
1.3%
4/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.

Other adverse events

Other adverse events
Measure
mHealth-CR
n=298 participants at risk
Participants in this arm will receive the mHealth-CR intervention. mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Usual Care
n=102 participants at risk
Participants in this arm receive usual care.
Cardiac disorders
Cardiac related events (Chest pain, planned procedure, and other)
8.1%
24/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
10.8%
11/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Musculoskeletal and connective tissue disorders
Body pain
3.7%
11/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
2.9%
3/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Musculoskeletal and connective tissue disorders
Fall
2.7%
8/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
0.98%
1/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
Investigations
Other events
7.0%
21/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
2.9%
3/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.

Additional Information

John Dodson, MD

NYU Langone Health

Phone: 6465012714

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place